Lemme GLP-1 Daily is not FDA-approved and is sold as a dietary supplement, not a medical treatment
At the 2024 Alzheimers Association International Conference, early results showed that people in early stages of Alzheimers who took the GLP-1 drug liraglutide daily for a year lost almost 50 percent less brain volume in key areas tied to memory and thinking
The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]
As evident, both peptides and steroids can have benefits related to muscle growth, weight loss, and other tissue-specific effects
The second effect is that our waste products move more slowly through the gastrointestinal tract
Cagrilintide is the long-acting analog with C20 fatty-acid albumin tether enabling once-weekly dosing for weight management